Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [21] Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).
    Rogers, Kerry Anne
    Thompson, Philip A.
    Allan, John Nathan
    Coleman, Morton
    Sharman, Jeff Porter
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng Seok
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Olivier
    Smith, Stephen D.
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal D.
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Gouill, Steven L. E.
    Oberic, Lucie
    Robak, Tadeusz
    Dua, Richa
    Frigault, Melanie M.
    Izumi, Raquel
    Nguyen, Dorothy
    Patel, Priti
    Yin, Ming
    Jurczak, Wojciech
    BLOOD, 2018, 132
  • [23] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
  • [24] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Badoux, Xavier C.
    Keating, Michael J.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lerner, Susan
    Sargent, Rachel L.
    Kantarjian, Hagop M.
    Ferrajoli, Alessandra
    BLOOD, 2011, 118 (21) : 448 - 448
  • [25] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
    Wendtner, Clemens
    Hillmen, Peter
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David Duane
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    de Parseval, Laure Moutouh
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 591 - 592
  • [26] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study
    Xu, Wei
    Song, Yongping
    Wang, Tingyu
    Yang, Shenmiao
    Liu, Lihong
    Hu, Yu
    Zhang, Wei
    Zhou, Jianfeng
    Gao, Sujun
    Ding, Kaiyang
    Zhang, Huilai
    Zhu, Zunmin
    Wang, Shunqing
    Xu, Bing
    Hu, Jianda
    Liu, Ting
    Ji, Chunyan
    Xia, Zhongjun
    Li, Yan
    Wang, Xin
    Bin Zhang
    Zhao, Renbin
    Li, Jianyong
    BLOOD, 2021, 138
  • [27] Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
    Xu, Wei
    Song, Yongping
    Wang, Tingyu
    Yang, Shenmiao
    Liu, Lihong
    Hu, Yu
    Zhang, Wei
    Zhou, Jianfeng
    Gao, Sujun
    Ding, Kaiyang
    Zhang, Huilai
    Zhu, Zunmin
    Wang, Shun-Qing
    Xu, Bing
    Hu, Jianda
    Liu, Ting
    Ji, Chunyan
    Xia, Zhongjun
    Li, Yan
    Wang, Xin
    Zhu, Huaqiang
    Zhao, Renbin
    Zhang, Bin
    Xu, Zhixin
    Li, Jianyong
    BLOOD, 2020, 136
  • [28] Acalabrutinib with Obinutuzumab in Treatment-Naive (TN) and Relapsed/Refractory (R/R) Patients with Chronic Lymphocytic Leukemia (CLL): 3-Year Follow-Up
    Woyach, Jennifer A.
    Rogers, Kerry A.
    Bhat, Seema
    Blachly, James
    Jianfar, Mojgan
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng
    Wang, Min Hui
    Byrd, John C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S281 - S281
  • [29] Acalabrutinib vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
  • [30] Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kriachok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Wang, Min Hui
    Yu, Ting
    Ghia, Paolo
    BLOOD, 2021, 138
12345